Provided By GlobeNewswire
Last update: Mar 25, 2025
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual function with the UroLift™ System (PUL) compared to Rezūm™ Water Vapor Therapy (WVTT).1
Read more at globenewswire.com129.15
-0.33 (-0.25%)
Find more stocks in the Stock Screener
TELEFLEX INC has a stellar value proposition. NYSE:TFX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.